34.83
0.90 (2.65%)
| Penutupan Terdahulu | 33.93 |
| Buka | 33.96 |
| Jumlah Dagangan | 881,369 |
| Purata Dagangan (3B) | 1,186,858 |
| Modal Pasaran | 3,747,464,704 |
| Harga / Buku (P/B) | 8.02 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2026 |
| EPS Cair (TTM) | -1.55 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.06% |
| Nisbah Semasa (MRQ) | 20.99 |
| Aliran Tunai Operasi (OCF TTM) | -118.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -67.74 M |
| Pulangan Atas Aset (ROA TTM) | -21.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.29% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Edgewise Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.75 |
|
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 104.04% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |